The HER2-enriched subtype, accounting for approximately 15%–20% of breast cancer is characterized by high expression of the ERBB2 gene, but shows considerable heterogeneity in its presentation which may also include differences in ER+ expression (ER+/ER-) (Turashvili and Brogi, 2017). Here, ERBB2 is linked to breast carcinoma.